STOCK TITAN

Gilead (NASDAQ: GILD) EVP exercises RSUs and withholds shares for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Gilead Sciences EVP and General Counsel Keeley M. Cain Wettan reported routine equity compensation activity. On June 10, 2026, 589 shares of common stock were acquired through a derivative exercise/conversion of restricted stock units at $0.00 per share.

On the same date, 283 shares of common stock were disposed of in a tax-withholding disposition at $121.48 per share to cover obligations tied to this equity event. After these transactions, the insider directly holds 5,643 shares of common stock and 19,997 restricted stock units, which vest over a four-year schedule.

Positive

  • None.

Negative

  • None.
Insider Cain Wettan Keeley M
Role EVP Gen Counsel, Legal & Comp
Type Security Shares Price Value
Exercise Restricted Stock Unit 589 $0.00 --
Exercise Common Stock 589 $0.00 --
Tax Withholding Common Stock 283 $121.48 $34K
Holdings After Transaction: Restricted Stock Unit — 19,997 shares (Direct, null); Common Stock — 5,643 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
RSUs exercised 589 shares Common stock acquired via derivative exercise/conversion on June 10, 2026
Tax-withholding shares 283 shares Shares delivered for tax liability at $121.48 per share on June 10, 2026
Tax-withholding price $121.48 per share Price used for 283-share tax-withholding disposition of common stock
Common shares held 5,643 shares Total common stock directly owned after transactions on June 10, 2026
RSUs outstanding 19,997 units Restricted stock units remaining after derivative transaction on June 10, 2026
Vesting schedule initial tranche 25% Portion of RSUs vesting on first anniversary of grant date
Ongoing vesting rate 6.25% quarterly Remaining RSUs vest 6.25% each quarter until fully vested
Restricted Stock Unit financial
"Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
tax-withholding disposition financial
"283 shares of common stock were disposed of in a tax-withholding disposition at $121.48 per share to cover obligations."
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative exercise/conversion financial
"589 shares of common stock were acquired through a derivative exercise/conversion of restricted stock units at $0.00 per share."
vesting schedule financial
"The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant."
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cain Wettan Keeley M

(Last)(First)(Middle)
333 LAKESIDE DRIVE

(Street)
FOSTER CITY CALIFORNIA 94404

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP Gen Counsel, Legal & Comp
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026M589A(1)5,643D
Common Stock06/10/2026F283D$121.485,360D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)06/10/2026M589 (2) (2)Common Stock589(1)19,997D
Explanation of Responses:
1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
2. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Remarks:
/s/ Amy Kim by Power of Attorney for Keeley M. Cain Wettan06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Gilead Sciences (GILD) report for Keeley M. Cain Wettan?

Gilead Sciences reported that EVP and General Counsel Keeley M. Cain Wettan exercised 589 restricted stock units into common shares and had 283 shares withheld in a tax-related disposition, both dated June 10, 2026, reflecting routine equity compensation activity.

How many Gilead (GILD) shares does Keeley M. Cain Wettan hold after this Form 4?

Following the June 10, 2026 transactions, Keeley M. Cain Wettan directly holds 5,643 shares of Gilead common stock. In addition, 19,997 restricted stock units remain outstanding, providing contingent rights to receive the same number of common shares as they vest over time.

What was the purpose of the 283-share disposition reported by Gilead (GILD)?

The 283-share disposition was a tax-withholding transaction, not an open-market sale. Shares were delivered at $121.48 per share to satisfy tax obligations related to the equity award event, as indicated by the Form 4 transaction code F and description provided.

How do the restricted stock units for Gilead (GILD) executive Keeley M. Cain Wettan vest?

Each restricted stock unit represents the right to receive one Gilead common share. The units vest over four years: 25% on the first grant anniversary, with the remaining balance vesting at 6.25% quarterly thereafter until fully vested, subject to continued service conditions.

Did the Gilead (GILD) Form 4 show an open-market buy or sell by Keeley M. Cain Wettan?

The Form 4 did not show any open-market purchases or sales. It reported a derivative exercise of 589 restricted stock units into common shares and a 283-share tax-withholding disposition, both classified as compensation-related rather than discretionary market trades.